FDAnews Drug Daily Bulletin

VIREXX ANNOUNCES THIRD QUARTER RESULTS

Nov. 15, 2005
A A

ViRexx Medical Corp., a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced its 2005 third quarter financial and operational results. "ViRexx's product pipeline continued to demonstrate clinical progress during the third quarter. Enrollment in the two Phase III trials for OvaRex MAb continues to grow and the trials are on schedule to complete enrollment in the first quarter of next year. Furthermore, we anticipate the Phase II OvaRex MAb trial will complete enrollment in the fourth quarter," said Marc Canton, President and Chief Operating Officer of ViRexx.

CCNMatthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=567323)